At a Glance
- Company: Novartis
- Location: Multiple sites across China (Beijing, Shanghai, Haiyan, Zhejiang)
- Deal value: >3.3 billion yuan total planned investment
- Focus area: Innovative medicines, radioligand cancer therapies, sterile manufacturing
- Next steps: Site upgrades, Shanghai campus phase II, Haiyan radioligand facility scale‑up
What happened?
Novartis announced plans to invest more than 3.3 billion yuan (about 460 million dollars) to expand its research and development, manufacturing capacity and overall operations footprint in China. The news was shared at the China Development Forum in Beijing, where CEO Vas Narasimhan underlined China’s importance to the company’s long‑term strategy.
Why does it matter?
China is already Novartis’ second‑largest market globally, and the new investment is intended to accelerate access to innovative medicines for Chinese patients. By expanding both conventional manufacturing and cutting‑edge radioligand therapy capabilities, Novartis is positioning China as a key hub for innovation, industrial scale‑up and oncology care.
Who’s behind it?
The initiative is led by Swiss pharmaceutical company Novartis, headquartered in Basel, with long‑standing operations in China.
Vas Narasimhan, who has attended the China Development Forum eight times, framed the move as part of Novartis’ ambition to deepen its role as a trusted healthcare partner in the country.
How was it achieved?
The company’s Changping plant in Beijing, a major site in its global network since 1987, has begun a fresh expansion and upgrade phase with about 1.5 billion yuan earmarked for new facilities and technologies in sterile preparations, liquid filling and packaging. In Shanghai, Novartis and partners plan to invest 1.8 billion yuan in a second‑phase development of its China headquarters campus, while a radioligand manufacturing facility in Haiyan county, Zhejiang province, built with 600 million yuan, has completed major construction to support PSMA‑targeted therapies approved for two indications in China in late 2025.
What’s next?
As the upgraded Changping facilities and the phase‑two Shanghai campus come online, Novartis is expected to scale innovation and local production, supporting more launches in the Chinese market. Once the Haiyan radioligand site reaches full capacity, the company anticipates shorter waiting times for cancer patients needing radioligand therapy, potentially broadening clinical use of these targeted treatments.
What are people saying?
Narasimhan described China as “critical to Novartis’ long‑term development and innovation,” signalling a strategic commitment beyond near‑term sales growth. The company emphasised that its China investments are designed to both expand local access and integrate Chinese operations more deeply into Novartis’ global innovation and manufacturing network.